Gilead
FDA Approves Biktarvy Label Update With Data for Use During Pregnancy
The FDA approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy for ...
APRIL 30, 2024
FDA Expands Indication of Biktarvy for Resistant HIV
The FDA expanded the indication for bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead) to ...
FEBRUARY 29, 2024
FDA Expands Indication for Veklury to Treat COVID-19 Patients With Renal Impairment
With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across ...
JULY 28, 2023
Oral Bridging of Lenacapavir Maintains Viral Suppression Among HIV Patients
Oral bridging of lenacapavir enabled patients to maintain viral suppression of their HIV after missed doses of ...
JULY 26, 2023
Man Sentenced to 15 Years for Distributing $230 Million in Fraudulent HIV Drugs
U.S. District Cour Judge Raag Singhal sentenced Lazaro Hernandez to 15 years for his part in the distribution of ...
JUNE 29, 2023
Remdesivir Reduces Readmission Risk by 16% Among Immunocompromised Patients With COVID-19
Remdesivir (Veklury, Gilead) may reduce risk for hospital readmission by as much as 16% among immunocompromised ...
APRIL 21, 2023
High Rates of PrEP Adherence and Persistence for F/TAF Patients
Patients who are naive to HIV PrEP and prescribed Descovy (Gilead) have a greater number of prescription dispenses, ...
JANUARY 6, 2023
FDA Approves Sunlenca for Adults With Resistant HIV
The FDA approved lenacapavir, a first-in-class, long-acting HIV capsid inhibitor, which is injected twice ...
DECEMBER 22, 2022
Remdesivir-Resistant Version of COVID-19 Detected in Organ Transplant Recipients
Two kidney transplant patients treated with immunosuppressive drugs, and who later had a lengthy COVID-19 ...
NOVEMBER 8, 2022
Federal Judge Freezes Assets of Those Involved in Allegedly Distributing Counterfeit HIV Meds
A New York federal judge froze the assets of several people and entities for allegedly running a nationwide scheme ...
OCTOBER 1, 2022
No Approval for Lenacapavir Due to Vial Compatibility Issues
The FDA issued a complete response letter for the New Drug Application for lenacapavir, an investigational, ...
MARCH 3, 2022
FDA Expands Use of Veklury for Mild to Moderate COVID-19
Previously limited to hospitalized patients, The FDA expands use of remdesivir to the outpatient setting.
JANUARY 24, 2022
